William Heiden

William K.
Heiden currently serves as Non-Executive Chairman at MacroGenics, Inc. since 2022, Independent Director at Atara Biotherapeutics, Inc. since 2015, Director at Third Pole, Inc. since 2021, and Director at both Corea Therapeutics and Boston Collegiate Charter School.
Former roles include President, Chief Executive Officer & Director at AMAG Pharma USA, Inc.; President, Chief Executive Officer & Director at Elixir Pharmaceuticals, Inc. from 2004 to 2008; President, Chief Executive Officer & Director at AMAG Pharmaceuticals, Inc. from 2017 to 2020; Non-Executive Chairman at rEVO Biologics, Inc. from 2012 to 2013; Director at LFB Biotechnologies SASU from 2006 to 2013; Director at Managed Health Care Associates, Inc. from 1996 to 1998; Director at Laboratoire Français du Fractionnement et des Biotechnologies; Director at Pharmaceutical Research & Manufacturers of America from 2016 to 2017; Director at ConjuChem Biotechnologies, Inc.; Vice President-Oncology at Schering-Plough Corp.
from 1987 to 2002; and President & Chief Operating Officer at Praecis Pharmaceuticals, Inc. from 2002 to 2004.
Education includes undergraduate studies at the University of Florida, an MBA from Johnson Graduate School of Management, and graduate studies at Université Catholique de Louvain.